Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RB0026 injection in Chinese toddlers 1–2 years
CTR20255199Phase 3Active
- Sponsor
- Reyoung (Suzhou) Biotechnology
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of RB0026 in respiratory syncytial virus disease (RSV), sponsored by Reyoung (Suzhou) Biotechnology. Started Jan 2026; status: active.
02
Drugs
RB0026
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on CTR20255199.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255199.